Drug Trial Radar · NCT05532696
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
61
Planned (sponsor's estimate)
Start
Sep 27, 2022
Primary completion
Nov 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Anbogen Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)
Conditions
- Advanced Solid Tumor
- Non Small Cell Lung Cancer
- HER2 Mutations
Interventions
ABT-101Drug
Patients will receive ABT-101 by oral administration on a 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the recommended Phase 2 Dose (RP2D) of ABT-101 in Part 1Time frame: 18 months
- Determine antitumor activity based on Objective Response Rate (ORR) in Part 2 in patients with NSCLC with targeted mutationTime frame: 36 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Taichung Veterans General Hospital
Taichung, Taiwan · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Taipei Medical Univresity Hospital
Taipei, Taiwan · Recruiting
Chang Gung Memorial Hospital, Linkou
Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.